The Future of Targeted Therapy for Leiomyosarcoma
Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has...
Main Authors: | Ryan A. Denu, Amanda M. Dann, Emily Z. Keung, Michael S. Nakazawa, Elise F. Nassif Haddad |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/5/938 |
Similar Items
-
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
by: Brandon M. Cope, et al.
Published: (2023-03-01) -
Primary adrenal leiomyosarcoma
by: Andrew Waack, BS, et al.
Published: (2023-03-01) -
Leiomyosarcoma, a rare smooth muscle cancer in the pancreas: An adjuvant radiotherapy treatment approach
by: Ali Taghizadeh Kermani, et al.
Published: (2023-06-01) -
Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma
by: Yukari Nagao, et al.
Published: (2023-03-01) -
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
by: Hiroshi Asano, et al.
Published: (2022-02-01)